FahyBGCoursinDB. Critical glucose control: the devil is in the details. Mayo Clin Proc. 2008;83(4):394-397.
4.
Van den BergheGSchetzMVlasselaersD. Clinical review. Intensive insulin therapy in critically ill patients: NICE-SUGAR or Leuven blood glucose target?J Clin Endocrinol Metab. 2009;94(9):3163-3170.
5.
FinferSHeritierS. The NICE-SUGAR (Normoglycaemia in Intensive Care Evaluation and Survival Using Glucose Algorithm Regulation) Study: statistical analysis plan. Crit Care Resusc. 2009;11(1):46-57.
6.
Van den BergheGBouillonRMesottenD. Glucose control in critically ill patients. N Engl J Med. 2009;361(1):89, author reply 91-92.
7.
EslamiSAbu-HannaAde JongeEde KeizerNF. Tight glycemic control and computerized decision-support systems: a systematic review. Eslami Intensive Care Med. 2009;35:1505-1517.
8.
TiwariHKSenMR. Emergence of vancomycin resistant Staphylococcus aureus (VRSA) from a tertiary care hospital from northern part of India. BMC Infect Dis. 2006;6:156.
9.
MoubareckCMeziane-CherifDCourvalinPPerichonB. VanA-type Staphylococcus aureus strain VRSA-7 is partially dependent on vancomycin for growth. Antimicrob Agents Chemother. 2009;53(9):3657-3663.